<DOC>
	<DOCNO>NCT02265861</DOCNO>
	<brief_summary>This research investigate response vascular active factor , vascular endothelial growth factor ( VEGF ) angiotensin-Ⅱ ( AT-Ⅱ ) ovary stimulation 24h patient polycystic ovary syndrome ( PCOS ) .Controled prospective clinical study involve 60 woman undergo vitro fertilization . Fifty-two patient PCOS 8 control case stimulate human chorionic gonadotropin ( HCG ) early follicular phase menstrual cycle ( 4st 7th day cycle ) .The blood sample injection ( 0 hour ) 3 , 6 , 12 , 18 24 hour point stimulation . VEGF , AT-Ⅱ measure radioimmunoassay .</brief_summary>
	<brief_title>Response VEGF AT-II HCG PCOS</brief_title>
	<detailed_description>After ovary stimulation , level VEGF typical PCOS patient obviously increase 3hs time point ( p &lt; 0.05 ) , difference VEGF time point among four group . As AT-Ⅱ , ovary stimulation , time point , AT-Ⅱ level serum patient different phenotype PCOS Rotterdam criterion higher control without PCOS . After ovary stimulation , AT-Ⅱ typical PCOS patient obviously increase 3hs time point , p &lt; 0.05 . The response VEGF AT-Ⅱ HCG woman typical PCOS high 24 hour stimulation early follicular phase . The response stimulation different patient different phenotype PCOS Rotterdam criterion . Serum VEGF AT-Ⅱ level possible contributor great risk develop OHSS patient typical PCOS early follicular phase 24 hour ovary stimulation .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<criteria>A total 60 woman recruit divided four group Rotterdam criterion accord three typical character : 1. biochemical characteristic hyperandrogenism ( HA ) 2. chronic anovulation 3. polycystic ovary morphology ( PCO ) . All woman match age ( &lt; 35 yr ) . All subject screen , endocrine disturbance ( thyroid , adrenal ) medical illness find . All patient hormonal preparation 3 month precede study .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Polycystic ovary syndrome ; Vascular endothelial growth factor ; Angiotensin-Ⅱ ; Ovarian hyperstimulation syndrome</keyword>
</DOC>